• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by BGM Group Ltd.

    5/7/26 4:15:08 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGM alert in real time by email
    6-K 1 tm2613923d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2026

     

    BGM Group Ltd

     

    No. 152 Hongliang East 1st Street, No. 1703, 

    Tianfu New District, Chengdu, 610200 

    People’s Republic of China 

    +86-028-64775180 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

    Change of Directors and Co-Chief Executive Officer

     

    Departure of Directors and Co-Chief Executive Officer

     

    On May 4, 2026, the board of directors (the “Board”) of BGM Group Ltd (the “Company”) received the resignation letters of Ms. Yuehua Ren (“Ms. Ren”) from her position as a director of the Company, Mr. Yuqing Li (“Mr. Li”) from his position as co-chief executive officer (“Co-CEO”) of the Company, Mr. Lin Zhang (“Mr. Zhang”) from his position as independent director of the Company and chairman of the compensation committee of the Board (the “Compensation Committee”), as well as member of the audit committee of the Board (the “Audit Committee”) and the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), and Mr. Maofan Tang (“Mr. Tang”) from his position as chairman of the Audit Committee and member of the Compensation Committee and the NCG Committee, effective from May 7, 2026.

     

    Ms. Ren’s, Mr. Li’s, Mr. Zhang’s and Mr. Tang’s resignations were due to their personal reasons and not as the result of any dispute or disagreement with the Company or the Board.

     

    Appointment of New Directors and Co-Chief Executive Officer

     

    Effective from May 7, 2026, for a three-year term of office, the Board appointed Ms. Huandi Zhao (“Ms. Zhao”) as Co-CEO and a director of the Company, Mr. Jianping Mao (“Mr. Mao”) as an independent director of the Company and the chairman of Compensation Committee and a member of the Audit Committee and NCG Committee, Mr. Junjie Wang (“Mr. Wang”) as an independent director of the Company and the chairman of the Audit Committee and a member of the Compensation Committee and NCG Committee.

     

    The biographical information of Ms. Zhao is set forth below:

     

    Ms. Zhao served as the Chief Technology Officer of Innovation Global Financial Group Limited from May 2021 to December 2025 and she was responsible for the strategic planning and implementation of the AI transformation of the company and daily management and operation of IT department. Previously, she served as the Vice President of IT department of Hebei Kanyu Insurance Agency Company Limited from February 2017 to December 2020. Ms. Zhao holds a Bachelor of Computer and Technology from Hebei University.

     

    Ms. Zhao does not have a family relationship with any director or executive officer of the Company. She has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    The biographical information of Mr. Mao is set forth below:

     

    Mr. Mao has served as the Financial Consultant of Huasu Capital from October 2012 to the present, where he is responsible for providing comprehensive financial planning and investment advisory services to high-net-worth individual and corporate clients. From July 2004 to September 2012, he served as an analyst at Guoshi Data Technology (Shanghai) Co., Ltd. Mr. Mao holds a bachelor of Mechanical Automation from Xinjian University.

     

    Mr. Mao does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    The biographical information of Mr. Wang is set forth below:

     

    Since November 2024, Mr. Wang has served as the Chief Financial Officer of Waltz Ltd., in which he is responsible for the company’s financial management, investment strategy, and capital markets and listing matters. From April 2023, he served as the Financial Controller of Shenzhen Huashuo New Material Application Technology Co., Ltd., overseeing financial management, investment activities, and preparation for potential listing. He worked as Project Assistant at Shenzhen Everbloom Investment Advisory Co., Ltd. from November 2021 to March 2023. Mr. Wang holds a master degree of Quantitative Finance and a bachelor degree of Mathematics and Finance from University of Technology Sydney.

     

     

     

    Mr. Wang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    Change in the Composition of Board Committees

     

    Effective May 7, 2026, the composition of the Board’s committees was reconstituted as follows:

     

    Audit Committee

     

    The Audit Committee of the Board shall now comprise Mr. Jianping Mao, Mr. Junjie Wang, and Ms. Waihua Xu. The Board has appointed Mr. Junjie Wang as the chairman of the Audit Committee.

     

    The Board has determined that each member of the Audit Committee meets the independence criteria set forth in Nasdaq Listing Rule 5605(a)(2) and the heightened independence requirements of Rule 10A-3(b)(1) under the U.S. Securities Exchange Act of 1934, as amended. The Board has also determined that Mr. Junjie Wang qualifies as an “audit committee financial expert” as defined in Item 407(d) of Regulation S-K and satisfies the financial sophistication requirements under Nasdaq Listing Rule 5605(c)(2)(A).

     

    Compensation Committee

     

    The Compensation Committee of the Board shall now comprise Mr. Jianping Mao, Ms. Waihua Xu and Mr. Junjie Wang. The Board has appointed Mr. Jianping Mao as the chairman of the Compensation Committee.

     

    As a foreign private issuer, as disclosed in the Form 20-F filed on January 27, 2025, the Company elected to follow its home country practice (Cayman Islands) in lieu of the requirements of Nasdaq Listing Rule 5605(d)(2), as permitted by Nasdaq Listing Rule 5615(a)(3). Accordingly, the Company’s Compensation Committee is not required to be composed solely of independent directors.

     

    NCG Committee

     

    The Nominating and Corporate Governance Committee of the Board shall now comprise Ms. Waihua Xu, Mr. Jianping Mao and Mr. Junjie Wang. Ms. Waihua Xu is the chairman of the Nominating and Corporate Governance Committee.

     

    As a foreign private issuer, as disclosed in the Form 20-F filed on January 27, 2025, the Company elected to follow its home country practice (Cayman Islands) in lieu of the requirements of Nasdaq Listing Rule 5605(e)(1), as permitted by Nasdaq Listing Rule 5615(a)(3). Accordingly, the Company’s Nominating and Corporate Governance Committee is not required to be composed solely of independent directors.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: May 7, 2026

     

      BGM Group Ltd
         
      By: /s/ Chen Xin
      Name:  Chen Xin
      Title: Co-Chief Executive Officer

     

    Get the next $BGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGM
    SEC Filings

    View All

    SEC Form 6-K filed by BGM Group Ltd.

    6-K - BGM Group Ltd. (0001779578) (Filer)

    5/18/26 8:30:10 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BGM Group Ltd.

    6-K - BGM Group Ltd. (0001779578) (Filer)

    5/7/26 4:15:08 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BGM Group Ltd.

    6-K - BGM Group Ltd. (0001779578) (Filer)

    4/30/26 4:15:12 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F

    CHENGDU, China, Feb. 26, 2026 (GLOBE NEWSWIRE) -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or "BGM")  announced on February 24, 2026, that it has received a notification (the "Notification") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") regarding its non-compliance with the Nasdaq Listing Rule 5250 (c)(1) as a result of the Company's failure to file its Annual Report on Form 20-F for the fiscal year ended September 30, 2025 (the "Form 20-F") in a timely manner. Pursuant to the Notification, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance from the date of receipt of the Notification and if the plan is accepted by Nas

    2/26/26 4:15:00 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM To Report First Half 2025 Unaudited Financial Results on July 24, 2025

    CHENGDU, China, July 23, 2025 /PRNewswire/ -- BGM Group (the "Company" or "BGM") (NASDAQ:BGM) today announced that it will release its unaudited financial results for the first half 2025 before the U.S. financial markets open on July 24, 2025 Eastern Daylight Time. About BGM  BGM Group Ltd. has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. In terms of AI application implementation, the group relies on advanced analytics and AI Agent technology, and utilizes the two platforms of Du Xiao Bao and Bao Wang to provide comprehensive and professional AI solutions and intelligent robot services

    7/23/25 6:36:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

    CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

    5/28/25 4:30:00 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Ren Yuehua

    3 - BGM Group Ltd. (0001779578) (Issuer)

    5/14/26 9:41:58 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Zhai Yaxuan

    3 - BGM Group Ltd. (0001779578) (Issuer)

    5/14/26 9:40:52 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Xu Waihua

    3 - BGM Group Ltd. (0001779578) (Issuer)

    5/14/26 9:39:45 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Leadership Updates

    Live Leadership Updates

    View All

    BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution

    CHENGDU, China, Feb. 28, 2025 /PRNewswire/ -- BGM Group Ltd (NASDAQ:BGM) (the "Company" or "BGM") today announced changes to its board of directors, marking the Company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin has tendered his resignation and will step down from his role as Chairman of the Company, effective March 1, 2025. He will be succeeded by Mr. Chen Xin, the current Chief Executive Officer of the Company, who will assume the position of Chairman. As the founder of the Company, Mr. Zhanchang Xin has, over the past six decades, has played a pivotal role in leading the Company through numerous challenges and milestones, including

    2/28/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry

    CHENGDU, China, Feb. 19, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) announced the establishment of the "Duxiaobao Management Committee," which will be fully responsible for the management and decision-making of the "Duxiaobao" ecosystem. This move signifies BGM Group's strategic entry into the field of artificial intelligence, aiming to accelerate the transformation of the insurance industry into the smart era through AI technology. The Duxiaobao Management Committee consists of industry leaders such as Xin Chen, Li Yuqing, Ge Peng, Zhao Qi, Ren Yong, Li Jun, Zhou Xin, and Wang Hui. The committee has appointed Li Yuqing as the CEO of Duxiaobao, with Li Jun, Ren Yong, Zhou Xin, and Tan

    2/19/25 7:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Financials

    Live finance-specific insights

    View All

    From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

    CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

    5/28/25 4:30:00 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

    CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

    4/21/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

    CHENGDU, China, March 19, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ:BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. ("YX"), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade

    3/19/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by BGM Group Ltd.

    SC 13D - BGM Group Ltd. (0001779578) (Subject)

    12/3/24 6:03:06 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BGM Group Ltd.

    SC 13D/A - BGM Group Ltd. (0001779578) (Subject)

    11/29/24 9:00:27 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Qilian International Holding Group Ltd.

    SC 13D - Qilian International Holding Group Ltd (0001779578) (Subject)

    10/16/24 4:19:46 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care